Study links exogenous insulin to higher mortality risk in diabetes

02/21/2013 | Healio

Data on 84,622 type 2 diabetes patients showed those on exogenous insulin treatment had a higher risk of complications -- including major cardiovascular events, renal conditions, cancer and all-cause mortality -- than those who were on other glucose-lowering therapies. "There is a clear need to review the way in which exogenous insulin is used in people with type 2 diabetes and to establish in detail the risk-benefit profile at differing stages of the natural history of the disease and in phenotypically different subgroups," researchers wrote in the Journal of Clinical Endocrinology and Metabolism.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC